Evaluation of the Effect of Naloxegol on Cardiac Repolarization: A Randomized, Placebo- and Positive-Controlled Crossover Thorough QT/QTc Study in Healthy Volunteers

Clinical Therapeutics

Volumn 35, Issue 12, 2013, Pages 1876-1883

  Gottfridsson, Christer ^a   Carlson, Glenn ^b   Lappalainen, Jaakko ^b   Sostek, Mark ^b  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Cardiac repolarization; Electrocardiography; Naloxegol; Opioid antagonist; Opioid induced constipation; Peripheral opioid receptor antagonist

Indexed keywords

MOXIFLOXACIN; NALOXEGOL; PLACEBO;

ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; ELECTROCARDIOGRAM; HEART RATE; HEART REPOLARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PHARMACODYNAMICS; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

CARDIAC REPOLARIZATION; ELECTROCARDIOGRAPHY; NALOXEGOL; OPIOID ANTAGONIST; OPIOID-INDUCED CONSTIPATION; PERIPHERAL Μ-OPIOID RECEPTOR ANTAGONIST;

ADULT; AZA COMPOUNDS; CONSTIPATION; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; HEALTHY VOLUNTEERS; HEART; HEART RATE; HUMANS; MALE; MIDDLE AGED; MORPHINANS; NALOXONE; NARCOTIC ANTAGONISTS; POLYETHYLENE GLYCOLS; QUINOLINES; YOUNG ADULT;

EID: 84890314074     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.09.019     Document Type: Article

References (29)

1. Chou R., Fanciullo G.J., Fine P.G., et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009, 10:113-130.
2. Trescot A.M., Helm S., Hansen H., et al. Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician 2008, 11(Suppl 2):S5-S62.
3. Panchal S.J., Muller-Schwefe P., Wurzelmann J.I. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract 2007, 61:1181-1187.
4. Allan L., Hays H., Jensen N.H., et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 2001, 322:1154-1158.
5. Bell T.J., Panchal S.J., Miaskowski C., et al. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med 2009, 10:35-42.
6. Cowan D.T., Wilson-Barnett J., Griffiths P., Allan L.G. A survey of chronic noncancer pain patients prescribed opioid analgesics. Pain Med 2003, 4:340-351.
7. Kalso E., Edwards J.E., Moore R.A., McQuay H.J. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004, 112:372-380.
8. Moore R.A., McQuay H.J. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther 2005, 7:R1046-R1051.
9. Kurz A., Sessler D.I. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003, 63:649-671.
10. Neumann T.A., van Paaschen H., Marcantonio A., et al. Evaluation of PEG-naloxol (NKTR-118) as an oral peripheral opioid antagonist in healthy male subjects: a double-blind, placebo-controlled, dose escalation crossover study. J Clin Pharmacol 2007, 47:1210.
11. Webster L, Dhar S. NKTR-118 significantly reverses opioid-induced constipation [abstract]. Accessed February 28, 2013. http://www.nektar.com/pdf/pipeline/NKTR-118/Nektar_poster118AAPM.pdf.
12. Yap Y.G., Camm A.J. Drug induced QT prolongation and torsades de pointes. Heart 2003, 89:1363-1372.
13. Martell B.A., Arnsten J.H., Krantz M.J., Gourevitch M.N. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol 2005, 95:915-918.
14. US Dept of Health and Human Services, Food and Drug Administration. Guidance for industry. E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Accessed February 22, 2013. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073153.pdf.
15. Dota C., Skallefell B., Edvardsson N., Fager G. Computer-based analysis of dynamic QT changes: toward high precision and individual rate correction. Ann Noninvasive Electrocardiol 2002, 7:289-301.
16. Dota C.D., Edvardsson N., Skallefell B., Fager G. PC-based ECG waveform recognition-validation of novel software against a reference ECG database. Ann Noninvasive Electrocardiol 2009, 14(Suppl 1):S42-S47.
17. Bloomfield D.M., Kost J.T., Ghosh K., et al. The effect of moxifloxacin on QTc and implications for the design of Thorough QT studies. Clin Pharmacol Ther 2008, 84:475-480.
18. Shah R.R. The significance of QT interval in drug development. Br J Clin Pharmacol 2002, 54:188-202.
19. Choi Y.S., Billings J.A. Opioid antagonists: a review of their role in palliative care, focusing on use in opioid-related constipation. J Pain Symptom Manage 2002, 24:71-90.
20. Wood J.D., Galligan J.J. Function of opioids in the enteric nervous system. Neurogastroenterol Motil 2004, 16(Suppl 2):17-28.
21. Parsells Kelly J., Cook S.F., Kaufman D.W., et al. Prevalence and characteristics of opioid use in the US adult population. Pain 2008, 138:507-513.
22. Sullivan M.D., Edlund M.J., Steffick D., Unutzer J. Regular use of prescribed opioids: association with common psychiatric disorders. Pain 2005, 119:95-103.
23. Campbell C.I., Weisner C., Leresche L., et al. Age and gender trends in long-term opioid analgesic use for noncancer pain. Am J Public Health 2010, 100:2541-2547.
24. Volkow N.D., McLellan T.A., Cotto J.H., et al. Characteristics of opioid prescriptions in 2009. JAMA 2011, 305:1299-1301.
25. Jensen M.K., Thomsen A.B., Hojsted J. 10-year follow-up of chronic non-malignant pain patients: opioid use, health related quality of life and health care utilization. Eur J Pain 2006, 10:423-433.
26. Mailis-Gagnon A., Lakha S.F., Ou T., et al. Chronic noncancer pain: characteristics of patients prescribed opioids by community physicians and referred to a tertiary pain clinic. Can Fam Physician 2011, 57:e97-e105.
27. McNicol E., Horowicz-Mehler N., Fisk R.A., et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain 2003, 4:231-256.
28. Breuer B., Cruciani R., Portenoy R.K. Pain management by primary care physicians, pain physicians, chiropractors, and acupuncturists: a national survey. South Med J 2010, 103:738-747.
29. Klepstad P., Kaasa S., Cherny N., et al. Pain and pain treatments in European palliative care units. A cross sectional survey from the European Association for Palliative Care Research Network. Palliat Med 2005, 19:477-484.